Drug General Information
Drug ID
D01LOE
Former ID
DNCL002886
Drug Name
LY2963016
Indication Type 1/2 diabetes [ICD9: 250, 278; ICD10:E08-E13] Phase 3 [525011]
Company
Boehringer Ingelheim Pharmaceuticals; Eli Lilly
Target and Pathway
Target(s) insulin Target Info Agonist [533242]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
cGMP-PKG signaling pathway
HIF-1 signaling pathway
FoxO signaling pathway
Oocyte meiosis
Regulation of autophagy
mTOR signaling pathway
PI3K-Akt signaling pathway
AMPK signaling pathway
Regulation of actin cytoskeleton
Insulin signaling pathway
Insulin secretion
Ovarian steroidogenesis
Progesterone-mediated oocyte maturation
Prolactin signaling pathway
Type II diabetes mellitus
Non-alcoholic fatty liver disease (NAFLD)
Type I diabetes mellitus
Maturity onset diabetes of the young
Aldosterone-regulated sodium reabsorption
Prostate cancer
PANTHER Pathway Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
Insulin/IGF pathway-protein kinase B signaling cascade
Pathway Interaction Database Insulin Pathway
Signaling events mediated by PTP1B
Arf6 trafficking events
Signaling events mediated by TCPTP
FOXA2 and FOXA3 transcription factor networks
ATF-2 transcription factor network
Insulin-mediated glucose transport
FOXA1 transcription factor network
PathWhiz Pathway Insulin Signalling
Pancreas Function
Leucine Stimulation on Insulin Signaling
Reactome Regulation of gene expression in beta cells
Insulin processing
Regulation of insulin secretion
IRS activation
Signal attenuation
Insulin receptor signalling cascade
Insulin receptor recycling
WikiPathways Senescence and Autophagy in Cancer
Differentiation Pathway
Insulin Processing
Nanoparticle triggered autophagic cell death
Cardiac Progenitor Differentiation
Adipogenesis
AGE/RAGE pathway
SREBP signalling
Cori Cycle
Synthesis, Secretion, and Deacylation of Ghrelin
Signaling by Insulin receptor
Regulation of beta-cell development
Integration of energy metabolism
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
Ref 525011ClinicalTrials.gov (NCT02302716) A Study of LY2963016 Compared to LANTUS in Adult Participants With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
Ref 533242Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus?) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab.2015 Aug;17(8):726-33.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.